Orchid Pharma Releases Revised Financials Incorporating Dhanuka Amalgamation and Strategic Acquisitions

Orchid Pharma Releases Revised Financials Incorporating Dhanuka Amalgamation and Strategic Acquisitions​

Orchid Pharma Limited has announced the approval of its revised Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The results reflect the operationalization of a major scheme of amalgamation with Dhanuka Laboratories Limited, as well as several significant strategic acquisitions.

The Board of Directors reviewed and approved these revised results during a meeting held on August 14, 2026. These financials are presented after giving effect to the merger between Dhanuka Laboratories Limited (the amalgamating company) and Orchid Pharma Limited (the amalgamated company), which had been sanctioned by the Hon'ble National Company Law Tribunal (NCLT) in Chennai. The amalgamation became effective from July 10, 2026, with an appointed date of April 01, 2024.

Strategic Acquisitions and IP Consolidation​

Beyond the corporate restructuring, Orchid Pharma Limited confirmed several strategic achievements impacting its global portfolio. The company successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH in Germany (on October 29, 2025) and AIIecra Therapeutics SAS in France (on August 01, 2025). This completion allows Orchid Pharma Limited to possess full global ownership of Enmetazobactam (the international brand name EXBLIFEP), consolidating rights previously held across multiple entities.

Furthermore, the company acquired 100% share capital of Weilchensee 1272. V GmbH in Germany and established it as a wholly-owned subsidiary named Orchid Pharma Europe GmbH effective July 30, 2025.

Financial Performance Snapshot​

The revised statements detail the consolidated performance for the quarter ended March 31, 2026. Key figures from the consolidated results include:


For the full year ended March 31, 2026, the consolidated Net Sales/Income from operations stood at 1,39,761.17 lakh. The company also utilized part of its Qualified Institutional Placement (QIP) net proceeds for investment in an OBPL (subsidiary) facility and repayment of outstanding borrowings.

Audit Qualifications on Consolidated Results​

The company released the results along with auditor's reports concerning the level of completeness regarding the consolidated financial statements. The independent auditor provided a qualified opinion on the revised consolidated annual financial results. This qualification primarily relates to certain subsidiary companies, including Orchid Pharmaceuticals Inc., USA, Bexel Pharmaceuticals Inc., USA, and Diakron Pharmaceuticals, Inc. USA.

The audit report notes that these specific subsidiaries' financial statements were unaudited but furnished by management for consolidation purposes. The auditor states that their opinion on the consolidated results is based solely on such unaudited financial statements regarding the amounts and disclosures included in respect of those entities.

The revised standalone annual financial results, however, received an unmodified opinion from the statutory auditors.

ORCHPHARMA Stock Price Movement​

Closing higher today, Orchid Pharma Limited shares edged up by 0.98%, settling at ₹1045.65 in after-hours trading. The stock traded within a range of ₹1035 to ₹1070 during the session, with a total volume of 64,474 shares recorded.